Results from the first six months of a two-year randomized, multicenter clinical study show that the blood glucose marker HbA1c is significantly lower in patients being managed by the TriabetesClinic system compared with the control group who is not.
The research, presented during a seminar for delegates at the meeting of the Swedish Society for Diabetology, aims to detect a minimum 5.5 mmol/mol decrease in HbA1c in the patients who self-report to the healthcare provider's remote care system using a smartphone app across four different treatment clinics over 24 months. Intention-to-treat analysis was applied to the interim results which show a significant median difference of 5.3 mmol/mol between the smartphone app and control groups during just six months.
"We found that it is clinically worthwhile to use the Triabetes app combined with the TriabetesClinic service to support the patients to improve metabolic control and lower their HbA1c values," said Kerstin Brismar, Professor of diabetes research at Karolinska Institutet. "Our analysis after six months showed that apps are a viable way to help control type 2 diabetes when the patient shares live data with their doctor or nurse, who in turn use a web-based triage service to monitor, coach and suggest treatment strategies."
"I welcome today's interim results since there are few rigorous studies that report on the clinical use of telemedicine systems in diabetes management," said Diabetes Tools' Chief Executive Officer Anders Weilandt.
There are 226 patients with Type 2 diabetes taking part in the study. They are spread across nine different primary care clinics in Poland run by the managed care group Medicover. The study uses medtech firm Diabetes Tools' Triabetes smartphone app for patients and TriabetesClinic, a web-based diabetes decision support service, for healthcare providers. This research is backed by academics from the Medical University of Warsaw and Karolinska Institutet in Stockholm, Sweden.
About Triabetes and Diabetes Tools
Triabetes is a smartphone app and online decision support service for people living with and caring for all forms of diabetes. Triabetes is from Diabetes Tools, a Swedish medical technology company that develops scientifically based Software-as-a-Service solutions. Triabetes is scalable. It can be used by individuals, doctors and treatment clinics, and can be integrated with large-scale Electronic Medical Record (EMR) systems.
Founded in 2005, Diabetes Tools is a privately held company located in Stockholm, Sweden. Diabetes Tools holds an ISO 13485 certificate, a compliance standard for creating medical devices and related services. Triabetes is a CE-marked medical software product registered for sale in the European Union. More information at http://www.diabetestools.se.